PharmaMar stops development of phase II compound
Enlarge image

IndustrySpain

PharmaMar stops development of phase II compound

11.04.2012 - Spanish drug developer will focus internal resources on its late-stage compounds.

Madrid – Spanish drug developer PharmaMar SA has quit the further development of its Phase II drug candidate Irvalec due to financial reasons. According to the company, the marine-derived cyclic peptide has shown notable activity in a trial to treat gastroesophageal cancer specifically in large cell undifferentiated carcinomas of the esophagus. However, this subtype is relatively rare and represents only 1% of all gastroesophageal cancers. The company, a member of listed Zeltia Group, will focus its resources on other compounds like Yondelis and Aplidin. Yondelis is approved outside the US to treat advanced or metastatic soft tissue sarcoma and relapsed platinum-sensitive ovarian cancers. The conotoxin has additionally been tested as first-line therapy for this indication. Aplidin is in phase III to treat multiple myeloma and in phase II for T-cell lymphoma.

http://www.european-biotechnology-news.com/news/news/2012-02/pharmamar-stops-development-of-phase-ii-compound.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%

FLOP

  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%

TOP

  • PROTHENA PLC (IE)49.60 USD25.8%
  • DBV Technologies (F)52.00 EUR20.9%
  • BIOINVENT INTERNATIONAL AB (S)2.60 SEK16.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)20.50 SEK-57.1%
  • CELLECTIS (F)30.10 EUR-26.4%
  • NORDIC NANOVECTOR (N)27.00 NOK-22.9%

TOP

  • 4SC (D)4.52 EUR366.0%
  • ADOCIA (F)64.00 EUR352.3%
  • WILEX (D)3.69 EUR334.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-70.4%
  • NEOVACS (F)1.11 EUR-69.7%

No liability assumed, Date: 29.06.2015